Satralizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Satralizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetinterleukin 6 receptor
Clinical data
Other namesSA237
ATC code
  • None
Identifiers
CAS Number
UNII
KEGG
Chemical and physical data
FormulaC6340H9776N1684O2022S46
Molar mass143416.47 g·mol−1

Satralizumab (INN;[1] formerly sapelizumab; development code SA237) is a humanized monoclonal antibody that is being investigated for the treatment of neuromyelitis optica spectrum disorder.[2]

This drug is being developed by Chugai Pharmaceutical, a member of the Roche Group. As of 2018, satralizumab is undergoing Phase III trials.[3]

References[edit]

  1. ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Satralizumab, American Medical Association.
  3. ^ "Chugai Presents Results from Phase III Study of Satralizumab in NMOSD at ECTRIMS 2018".